Résultat de l'étude randomisée EARLY ! https://t.co/dvjNTKczWZ
Not infrequently we ignore our own data and guidelines for the sake of avoiding a few extra hospitalization days in a shrinking minority of patients.
Optimal Timing of Intervention in NSTE-ACS Without Pre-Treatment: The ... https://t.co/Ctwo2C3wv2
RT @GreggWStone: Exactly. This is why if it is true ACS, you either should pre-load (ideally ticagrelor) and wait for it to become effecti…
RT @ncurzen: Is there a downside to the NICE recommendation to give prasugrel only after the angio result? This isn’t shown definitively h…
RT @GreggWStone: Exactly. This is why if it is true ACS, you either should pre-load (ideally ticagrelor) and wait for it to become effecti…
RT @GreggWStone: Exactly. This is why if it is true ACS, you either should pre-load (ideally ticagrelor) and wait for it to become effecti…
RT @ncurzen: Is there a downside to the NICE recommendation to give prasugrel only after the angio result? This isn’t shown definitively h…
Is there a downside to the NICE recommendation to give prasugrel only after the angio result? This isn’t shown definitively here... but there is a hint - & it is snuggly concern
RT @GreggWStone: Exactly. This is why if it is true ACS, you either should pre-load (ideally ticagrelor) and wait for it to become effecti…
RT @GreggWStone: Exactly. This is why if it is true ACS, you either should pre-load (ideally ticagrelor) and wait for it to become effecti…
RT @GreggWStone: Exactly. This is why if it is true ACS, you either should pre-load (ideally ticagrelor) and wait for it to become effecti…
Exactly. This is why if it is true ACS, you either should pre-load (ideally ticagrelor) and wait for it to become effective, or use IV cangrelor. And other studies have shown that waiting in high risk ACS only causes extra events.
RT @DrJLFerreiro: Interesting article by Lemesle and colleagues. RCT regarding timing of invasive strategy in #NSTEACS patients not pretrea…
RT @DrJLFerreiro: My POV (editorial) about the article and pretreatment with #iP2Y12 in #NSTEACS. An individualized approach is better... P…
RT @DrJLFerreiro: Interesting article by Lemesle and colleagues. RCT regarding timing of invasive strategy in #NSTEACS patients not pretrea…
RT @DrJLFerreiro: Interesting article by Lemesle and colleagues. RCT regarding timing of invasive strategy in #NSTEACS patients not pretrea…
RT @DrJLFerreiro: My POV (editorial) about the article and pretreatment with #iP2Y12 in #NSTEACS. An individualized approach is better... P…
RT @DrJLFerreiro: Interesting article by Lemesle and colleagues. RCT regarding timing of invasive strategy in #NSTEACS patients not pretrea…
RT @DrJLFerreiro: My POV (editorial) about the article and pretreatment with #iP2Y12 in #NSTEACS. An individualized approach is better... P…
RT @DrJLFerreiro: Interesting article by Lemesle and colleagues. RCT regarding timing of invasive strategy in #NSTEACS patients not pretrea…
RT @DrJLFerreiro: My POV (editorial) about the article and pretreatment with #iP2Y12 in #NSTEACS. An individualized approach is better... P…
RT @DrJLFerreiro: My POV (editorial) about the article and pretreatment with #iP2Y12 in #NSTEACS. An individualized approach is better... P…
RT @DrJLFerreiro: My POV (editorial) about the article and pretreatment with #iP2Y12 in #NSTEACS. An individualized approach is better... P…
My POV (editorial) about the article and pretreatment with #iP2Y12 in #NSTEACS. An individualized approach is better... Pre-Treatment With Oral P2Y12 Inhibitors in NSTEACS https://t.co/fKXnEfgoga @hbellvitge @secardiologia @shci_sec @JACCJournals
Interesting article by Lemesle and colleagues. RCT regarding timing of invasive strategy in #NSTEACS patients not pretreated with iP2Y12... Optimal Timing of Intervention in NSTE-ACS Without Pre-Treatment https://t.co/1E4cNV7Bs4 https://t.co/n8yEqf9G83
RT @ncurzen: Amongst other things this excellent trial raises again the question about whether we should use dapt as a medical therapy if w…
RT @agershlick: Interesting study but own goal to not provide appropriate standard of care DAPT till angio. Also median time to SoC angio s…
Interesting study but own goal to not provide appropriate standard of care DAPT till angio. Also median time to SoC angio short c.f most centres + short follow-up. While direction travel is towards early angio in high risk NSTEMI, our robust RAPID N-STEMI
Amongst other things this excellent trial raises again the question about whether we should use dapt as a medical therapy if we delay angio in nstemi? The headline is that early angio is far superior to delayed in high risk nstemi @agershlick @SimonCorbet
RT @hect2701: “Without pre-treatment, a very early invasive strategy was associated with a significant reduction in ischemic events at the…
RT @hect2701: “Without pre-treatment, a very early invasive strategy was associated with a significant reduction in ischemic events at the…
RT @hect2701: “Without pre-treatment, a very early invasive strategy was associated with a significant reduction in ischemic events at the…
Optimal Timing of Intervention in NSTE-ACS Without Pre-Treatment | JACC: Cardiovascular Interventions https://t.co/oPVqPDQHcB
RT @hect2701: “Without pre-treatment, a very early invasive strategy was associated with a significant reduction in ischemic events at the…
EARLY Randomized Trial @JACCJournals Delayed (12 to 72 h) vs. very early (within 2 h) intervention in patients intermediate- or high-risk NSTE-ACS 👇👇
RT @hect2701: “Without pre-treatment, a very early invasive strategy was associated with a significant reduction in ischemic events at the…
RT @hect2701: “Without pre-treatment, a very early invasive strategy was associated with a significant reduction in ischemic events at the…
RT @hect2701: “Without pre-treatment, a very early invasive strategy was associated with a significant reduction in ischemic events at the…
RT @hect2701: “Without pre-treatment, a very early invasive strategy was associated with a significant reduction in ischemic events at the…
“Without pre-treatment, a very early invasive strategy was associated with a significant reduction in ischemic events at the time of percutaneous coronary intervention in patients with intermediate- and high-risk NSTE-ACS “ https://t.co/briruchWrn https:/
NSTE-ACS, no pre-cath P2Y12 Early invasive (<2h) strategy had ⬇️ recurrent ischemic events, but only in first 72hr (prior to cath in delayed group, 12-72h). Wonder if ⬆️later HF in delayed group @NinoNJ @CianPMcCarthy @RomitB_MD @ShawnXLiMD @jonathan_sa
Optimal Timing of Intervention in NSTE-ACS Without Pre-Treatment | JACC: Cardiovascular Interventions https://t.co/oPVqPDz6l3
Optimal Timing of Intervention in NSTE-ACS Without Pre-Treatment https://t.co/xX6a55c4Qi